Sandia National Laboratories is seeking one or more business partners to commercialize a technology they have developed for point-of-care diagnostics based on centrifugal microfluidics.
The technology transfer opportunity, called SpinDx, is based on an innovative technique for conducting simultaneous multiplexed immunoassays and white blood cell counts from a single finger prick of whole blood. The technique is based on sedimentation principles within a disposable microfluidic disk, in which all sample processing and detection is automated by centrifugal force.
Sandia describes SpinDx as being highly flexible, enabling customized assay development and consolidated disk prototyping with rapid turnaround time. Other listed features include:
• Multiplexed: Up to 64 parallel assays from a single sample
• Speed: <15 min sample-to answer
• Minimally-invasive: <20μL sample input (i.e., finger puncture whole blood sample)
• Disposable: Single-use disks pre-loaded with all reagents for off-the-shelf processing
• Simple/robust: Based on well-established principles requiring unsophisticated instrumentation
Commercial licensees will have the opportunity to obtain a license to the intellectual properties for reasonable compensation. It is expected that the any company that works with Sandia to develop the SpinDx technology will incorporate it into a commercial product. Further details are available under Solicitation Number: 12-373. Additional opportunities for licensing are available at the Sandia Licensing and Technology Transfer website.
Sandia National Laboratories is a multi-program laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy’s National Nuclear Security Administration under contract DE-AC04-94AL85000.
View Profile: Sandia National Laboratories
